CymaBay Therapeutics Inc. (NASDAQ:CBAY) saw an upside of 15.89% to close Tuesday at $7.66 after adding $1.05 on the day. The 5-day average trading volume is 2,542,220 shares of the company’s common stock. It has gained $7.82 in the past week and touched a new high 3 times within the past 5 days. An average of 1,627,200 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,000,426.
CBAY’s 1-month performance is 54.44% or $2.18 on its low of $5.27 reached on 12/27/22. The company’s shares have touched a 52-week low of $1.67 and high of $7.15, with the stock’s rally to the 52-week high happening on 01/24/23. YTD, CBAY has achieved 22.17% or $1.39 and has reached a new high 6 times. However, the current price is up 7.15% from the 52-week high price.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
CBAY stock has a beta of 0.11. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 11.10.
CymaBay Therapeutics Inc.’s quick ratio for the period ended September 29 was 12.20, with the current ratio over the same period at 12.20. As well, the company’s long term debt to equity for the quarter ending September 29 was 1.43, while the total debt to equity was 1.43.
For the quarterly period ending September 29 this year, CymaBay Therapeutics Inc.’s cash and short-term investments amounted to $122.72 million against total debt of $87.0 million. Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 7.47% to -$24.51 million, while revenue of -$27.09 million was -10.53% off the previous quarter. Analysts expected CBAY to announce -$0.3 per share in earnings in its latest quarter, but it posted -$0.28, representing a 6.70% surprise. EBITDA for the quarter stood at more than -$21.21 million. CBAY stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 99.07 million, with total debt at $87.0 million. Shareholders hold equity totaling $84.68 million.
Let’s look briefly at CymaBay Therapeutics Inc. (CBAY) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 78.29% to suggest the stock is trending Overbought, with historical volatility in this time period at 82.54%.
The stock’s 5-day moving average is $6.91, reflecting a +12.81% or $0.87 change from its current price. CBAY is currently trading +52.89% above its 20-day SMA, +119.48% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +137.89% and SMA200 by+136.42%.
Stochastic %K and %D was 80.67% and 78.19% and the average true range (ATR) pointed at 0.51. The RSI (14) points at 77.16%, while the 14-day stochastic is at 92.56% with the period’s ATR at 0.45. The stock’s 9-day MACD Oscillator is pointing at 0.40 and 0.64 on the 14-day charts.
Analysts offering their rating for CBAY stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate CBAY as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 9 have offered a “buy” rating.
What is CBAY’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $8.00 and a high of $17.00, with their median price target at $10.00. Looking at these predictions, the average price target given by analysts is for CymaBay Therapeutics Inc. (CBAY) stock is $10.44.